BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stem MS, Todorich B, Faia LJ. Ocular Pharmacology for Scleritis: Review of Treatment and a Practical Perspective. J Ocul Pharmacol Ther. 2017;33:240-246. [PMID: 28355124 DOI: 10.1089/jop.2016.0127] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Suarez Avellaneda NA, Bobadilla Marroquin Y, Rodriguez Lopez CE, Loya Carrera MF, Pedroza-Seres M. Clinical Profile, Systemic Association, Treatment and Visual Outcome of Patients with Scleritis in an Eye Care Center in Mexico City. Ocul Immunol Inflamm 2022;:1-6. [PMID: 35258418 DOI: 10.1080/09273948.2022.2042317] [Reference Citation Analysis]
2 Abdel-aty A, Gupta A, Del Priore L, Kombo N. Management of noninfectious scleritis. Ophthalmol Eye Dis 2022;14:251584142110708. [DOI: 10.1177/25158414211070879] [Reference Citation Analysis]
3 Vermeirsch S, Testi I, Pavesio C. Choroidal involvement in non-infectious posterior scleritis. J Ophthalmic Inflamm Infect 2021;11:41. [PMID: 34705127 DOI: 10.1186/s12348-021-00269-9] [Reference Citation Analysis]
4 Abdel-Aty A, Kombo N. Factors affecting the resolution of acute non-infectious anterior scleritis. Br J Ophthalmol 2021:bjophthalmol-2021-318808. [PMID: 34210671 DOI: 10.1136/bjophthalmol-2021-318808] [Reference Citation Analysis]
5 Zhao YJ, Zou YL, Lu Y, Tu MJ, You ZP. Intravitreal dexamethasone implant — a new treatment for idiopathic posterior scleritis: A case report. World J Clin Cases 2021; 9(2): 422-428 [PMID: 33521111 DOI: 10.12998/wjcc.v9.i2.422] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Ruiz-Lozano RE, Garza-Garza LA, Davila-Cavazos O, Foster CS, Rodriguez-Garcia A. The clinical and pathogenic spectrum of surgically-induced scleral necrosis: A review. Surv Ophthalmol 2021;66:594-611. [PMID: 33422510 DOI: 10.1016/j.survophthal.2020.12.008] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
7 Sánchez-Bilbao L, Martínez-López D, Revenga M, López-Vázquez Á, Valls-Pascual E, Atienza-Mateo B, Valls-Espinosa B, Maiz-Alonso O, Blanco A, Torre-Salaberri I, Rodríguez-Méndez V, García-Aparicio Á, Veroz-González R, Jovaní V, Peiteado D, Sánchez-Orgaz M, Tomero E, Toyos-Sáenz de Miera FJ, Pinillos V, Aurrecoechea E, Mora Á, Conesa A, Fernández-Prada M, Troyano JA, Calvo-Río V, Demetrio-Pablo R, González-Mazón Í, Hernández JL, Castañeda S, González-Gay MÁ, Blanco R. Anti-IL-6 Receptor Tocilizumab in Refractory Graves' Orbitopathy: National Multicenter Observational Study of 48 Patients. J Clin Med 2020;9:E2816. [PMID: 32878150 DOI: 10.3390/jcm9092816] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
8 Kandarakis SA, Petrou P, Papakonstantinou E, Spiropoulos D, Rapanou A, Georgalas I. Ocular nonsteroidal inflammatory drugs: where do we stand today? Cutan Ocul Toxicol 2020;39:200-12. [PMID: 32338073 DOI: 10.1080/15569527.2020.1760876] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Khan RS, Rizvi S, Syed BA, Bielory L. Current market trends in anterior ocular inflammatory disease landscape. Current Opinion in Allergy & Clinical Immunology 2019;19:503-9. [DOI: 10.1097/aci.0000000000000562] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Bielefeld P, Saadoun D, Héron E, Abad S, Devilliers H, Deschasse C, Trad S, Sène D, Kaplanski G, Sève P. [Scleritis and systemic diseases: What should know the internist?]. Rev Med Interne 2018;39:711-20. [PMID: 29496270 DOI: 10.1016/j.revmed.2018.02.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]